HeartMate II left ventricular assist device; early European experience

Authors:
  • KSKare Sander
    Kare Sander
  • JLJaap Lahpor
    Jaap Lahpor
  • HAHenrik Ahn
    Henrik Ahn
  • PLPierre-Yves Litzler
    Pierre-Yves Litzler
  • SDStavros G. Drakos
    Stavros G. Drakos
  • FMFrancesco Musumeci
    Francesco Musumeci
  • CSChristian Schlensak
    Christian Schlensak
  • IFIvar Friedrich
    Ivar Friedrich
  • RGRonny Gustafsson
    Ronny Gustafsson
Publisher website
Google Scholar
Abstract
The novel axial flow left ventricular assist device HeartMate II was introduced into clinical practice in Europe as part of the pilot study and after CE approval in November 2005. In order to get an overview of the use and performance of the device in Europe a group of investigators was founded to compare the initial results. In a retrospective analysis of the first 101 consecutive cases in Europe, data were collected with regard to postoperative outcome and severe adverse events and anticoagulation protocols. Results were stratified by intention to treat as a bridge to transplant or as chronic support therapy in heart failure (destination therapy). In 70% of patients, the HeartMate II was intended as a bridge to transplant therapy, in 30%, it was used as a destination therapy device. The perioperative mortality post implant was 20% in the bridge to transplant patients and 7% in the destination therapy arm. However, after 1 year a comparable survival was observed in both groups (69% destination therapy, 63% bridge to transplant). Main causes of death were multiple organ failure (n=12) and cerebrovascular accidents (n=5). All, but one cerebrovascular accident occurred in the first 9 days after surgery. Only one other death was reported thereafter and there was no mechanical failure of the device. Even in the early experience the HeartMate II was used as a chronic support device in a substantial number of patients in Europe. Although the total experience is still limited, the incidence of cerebrovascular accidents is very low and the survival beyond the perioperative period is excellent.